Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003781 · ClinicalTrials.gov registry record · Phase 2
Docetaxel in Treating Patients With Stage IV Prostate Cancer
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00003781 is a Phase 2 study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 25 participants.
The verdict
NCT00003781, a Phase 2 study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial of docetaxel in treating patients who have stage IV prostate cancer that has not responded to hormone therapy.
Interventions
- DRUG docetaxel
- PROCEDURE quality-of-life assessment
- PROCEDURE pain therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1998-12 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003781
The ClinicalTrials.gov registry entry for NCT00003781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which docetaxel is the first listed.
NCT00003781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003781 about?
NCT00003781 is a clinical study titled "Docetaxel in Treating Patients With Stage IV Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial of docetaxel in treating patients who have stage IV prostate cancer that has not responded to hormone therapy.
What is the current status of trial NCT00003781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1998-12. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00003781?
The interventions under investigation include: docetaxel (DRUG), quality-of-life assessment (PROCEDURE), pain therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00003781?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.